First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)

被引：0
|
作者：
Kok, M. [1 ]
Voorthuis, R. A. B. [2 ]
De Boo, L. [2 ]
van Rossum, A. G. J. [2 ]
Mandjes, I. [3 ]
Balduzzi, S. [4 ]
Chelushkin, M. [5 ]
Rosenberg, E. H. [6 ]
Horlings, H. M. [7 ]
Loo, C. E. [8 ]
Heijns, J. B. [9 ]
Agterhof, M. [10 ]
De Valk, B. [11 ]
Riel, A-M. V. [12 ]
Van der Velden, A. [13 ]
Dercksen, M. [14 ]
Imholz, A. [15 ]
van Leeuwen-Stok, A. E. [16 ]
Oosterkamp, H. M. [17 ]
Linn, S. [18 ]
机构：
[1] Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Mol Pathol Dept, Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands
[4] NKI Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands
[5] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Tumor Biol & Immunol, Amsterdam, Netherlands
[6] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands
[7] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Pathol, Amsterdam, Netherlands
[8] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Radiol, Amsterdam, Netherlands
[9] Amphia Ziekenhuis Locat Molengracht, Oncol Dept, Breda, Netherlands
[10] St Antonius Hosp, Interne Geneeskunde, Nieuwegein, Netherlands
[11] Spaarne Hosp Hoofddorp, Med Oncol Dept, Hoofddorp, Netherlands
[12] ETZ Elisabeth Hosp, Med Oncol Dept, Tilburg, Netherlands
[13] Martini Hosp, Internal Med Dept, Groningen, Netherlands
[14] Maxima Med Ctr Veldhoven, Med Oncol, Veldhoven, Netherlands
[15] Deventer Ziekenhuis, Med Oncol, Deventer, Netherlands
[16] BOOG Study Ctr, Dutch Breast Canc Res Grp, Utrecht, Netherlands
[17] HMC Haaglanden Med Ctr Westeinde, Med Oncol, The Hague, Netherlands
[18] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2258
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA20
引用
收藏
页码：1213 / 1213
页数：1
相关论文
共 50 条
  • [1] Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)
    Van Rossum, Annelot G. J.
    Mandjes, Ingrid A. M.
    Van Werkhoven, Erik
    Van Tinteren, Harm
    Van Leeuwen-Stok, A. Elise
    Nederlof, Petra
    Portielje, Johanna E. A.
    Van Alphen, Robbert J.
    Platte, Els
    Van den Broek, Daan
    Huitema, Alwin
    Kok, Marleen
    Linn, Sabine C.
    Oosterkamp, Hendrika M.
    BREAST CARE, 2021, 16 (06) : 598 - 606
  • [2] ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
    Cortes Salgado, A.
    Perez Garcia, J. M.
    Cortez Castedo, S. P.
    Gion Cortes, M.
    Morales Murillo, S.
    Blancas Lopez-Barajas, I.
    Blanch, S.
    Calvo Plaza, I.
    Diaz Fernandez, N.
    Marme, F.
    Martinez Bueno, A.
    Taberner Bonastre, M. T.
    De laurentiis, M.
    Ruiz Borrego, M.
    Schmid, P.
    Guarneri, V.
    Gligorov, J.
    Sampayo-Cordero, M.
    Llombart Cussac, A.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S221 - S221
  • [3] IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
    Emens, Leisha A.
    Adams, Sylvia
    Loi, Sherene
    Schneeweiss, Andreas
    Rugo, Hope S.
    Winer, Eric P.
    Barrios, Carlos H.
    Dieras, Veronique
    de la Haba-Rodriguez, Juan
    Gianni, Luca
    Chui, Stephen Y.
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
    Emens, L.
    Adams, S.
    Loi, S.
    Schmid, P.
    Schneeweiss, A.
    Rugo, H.
    Chui, S.
    Winer, E.
    CANCER RESEARCH, 2016, 76
  • [5] Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
    Cortes, Maria
    Salgado, Alfonso Cortes
    Murillo, Serafin Morales
    Blancas, Isabel
    Cortez, Patricia
    Plaza, Isabel Calvo
    Fernandez, Nieves Diaz
    Martinez-Bueno, Alejandro
    Ruiz-Borrego, Manuel
    Blanch, Salvador
    Llabres, Elisenda
    Marme, Frederik
    Schmid, Peter
    Guarneri, Valentina
    Gligorov, Joseph
    Perez-Garcia, Jose Manuel
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Cussac, Antonio Llombart
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Results from ALICE - Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial
    Kyte, Jon Amund
    Rossevold, Andreas H.
    Andresen, Nikolai K.
    Bjerre, Christina Annette
    Gilje, Bjornar
    Jakobsen, Erik Hugger
    Raj, Sunil Xavier
    Falk, Ragnhild Sorum
    Borgen, Elin
    Jahr, Thea
    Garred, Oystein
    Lomo, Jon
    Mathiesen, Randi Margit
    Naume, Bjorn
    CANCER RESEARCH, 2023, 83 (05)
  • [7] Results From ALICE: Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 9
  • [8] Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
    Schmid, P.
    McArthur, H. L.
    Cortes, J.
    Xu, B.
    Cardoso, F.
    Casalnuovo, M. L.
    Demirci, U.
    Freitas, R., Jr.
    Ghosh, J.
    Hegg, R.
    Iwata, H.
    Chuken, Y. A. Lopez
    Nechaeva, M.
    Robson, M. E.
    Villalobos Valencia, R.
    Lloyd, A.
    D'Cruz, C.
    Foxley, A.
    Park, Y. H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1212 - 1213
  • [9] nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
    Yardley, D. A.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    de la Cruz-Merino, L.
    Wilks, S.
    O'Shaughnessy, J.
    Gluck, S.
    Li, H.
    Miller, J.
    Barton, D.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1763 - 1770
  • [10] nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial
    Yardley, D.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    Merino, L. de la Cruz
    Wilks, S.
    O'Shaugnessy, J.
    Gluck, S.
    Li, H.
    Beck, R.
    Barton, D.
    Harbeck, N.
    CANCER RESEARCH, 2017, 77
12345